Resistant hypertension (RHTN) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications (uncontrolled RHTN (UCRH)) and patients whose BP is controlled with use of four or more drugs (controlled RHTN (CRH)). It is unknown whether endothelial function and nocturnal drop demonstrate a similar pattern in patients with CRH and UCRH. We examined circadian BP patterns and vascular function in these patients. In all, 40 CRH and 26 UCRH patients, and 25 normotensives underwent biochemical testing, ambulatory BP monitoring, determination of brachial artery responses to endothelial-dependent (flow-mediated; dilation (FMD)) and independent (nitroglycerin mediated) stimuli. The nighttime drop in systolic BP (SBP) and diastolic BP (DBP) was less pronounced in UCRH than in CRH (SBP, 1.9±1.6 versus 4.9 ± 1.7%; DBP, 7.5 ± 1.8 versus 10.9 ± 1.8%, UCRH and CRH, respectively; Po0.05). FMD was greater in control group compared with RHTN patients. Patients with UCRH had significantly impaired FMD compared with CRH (5.9 ± 2.3% versus 7.1 ± 5.1%; Po0.0001). Therefore, UCRH patients have less nocturnal dipping and a more impaired endothelial response compared with CRH patients. These findings suggest that important differences among patients with RHTN may allow identify subgroups with increased cardiovascular risk.
Introduction
Resistant hypertension (RHTN) is defined as blood pressure (BP) that remains above goal (140/ 90 mm Hg) in spite of the concurrent use of three or more antihypertensive agents of different classes. Ideally, one of the agents should be a diuretic and all agents should be prescribed at optimal doses. This revised definition includes a subgroup of resistant hypertensive patients whose BP is controlled with use of four or more antihypertensive medications, and are referred to as having 'controlled RHTN' (CRH). 1 This new definition was intended to identify patients with difficult-to-treat hypertension, both controlled and uncontrolled, who are at high risk of having potentially reversible secondary causes of hypertension and may benefit from specific diagnostic and therapeutic interventions. 2 Although this new definition may be useful in terms of categorizing a broader group of patients with hypertension resistant to treatment, some important pathophysiological and clinical questions should be addressed before considering CRH and uncontrolled RHTN (UCRH) part of the same patient group. For example, one of the most important characteristics found in true resistant hypertensive subjects as diagnosed by ambulatory BP monitoring (ABPM) is a blunted drop in nocturnal BP compared with normotensive (NT) subjects. [3] [4] This lack of or reduced nocturnal dipping is associated with a markedly higher risk of cardiovascular morbidity, target-organ deterioration and secondary hypertension. [5] [6] Furthermore, as we have previously reported, endothelium-dependent and -independent arterial vasodilatation are clearly reduced in uncontrolled hypertensive patients compared with NT subjects. 7 However, the relation between the nocturnal drop in BP and endothelial function in CRH compared with UCRH patients has not been previously determined. Thus, the objective of this study was to determine whether the relation between nocturnal dipping status and vascular function in CRH and UCRH patients are similar.
Methods
This study was approved by the Institutional Research Ethics Board at the Medicine School, State University of Campinas (Campinas, Brazil), and each subject signed an informed written consent form. RHTN was defined as uncontrolled office BP (4140/90 mm Hg) despite the use of an optimal regimen consisting of at least three antihypertensive drugs, including a diuretic, or controlled office BP on four drugs or more. 1 
Subjects
We evaluated patients referred to the Outpatient Resistant Hypertension Clinic of the Campinas State University for difficult-to-control hypertension. These patients are followed regularly for a period of at least 6 months, during which time it is made an optimization of the previous treatment before they are considered to be true resistant hypertensive patients. In all, 66 patients with RHTN were identified from this group and included in the study. The mean time of hypertension diagnosis was 8.4 years. A control group consisted of 25 NT volunteers. Considering the heterogeneity of the Brazilian population, we did not report differences in ethnicity in this study. According to the latest survey of the Brazilian Geographic Institute, 53.4% of all the people are white, 6.1% blacks and 38.9% admixture populations. The specific southeastern region of Brazil, where Campinas State University is located, has 80% of the European immigrants.
All individuals had a complete history and physical examination, electrocardiography and laboratory testing. Patients with secondary forms of hypertension, ischemic heart disease, liver disease, strokes, peripheral vascular disease, inflammatory disease, smokers or any other major diseases were excluded. Diabetic patients were not excluded from the study, as there is an elevated prevalence of this condition among RHTN patients. The prevalence of diabetes was similar in both groups 15.3% in the UCRH and 17.5% in the CRH (P ¼ 0.55). Patients were evaluated for adherence to treatment, 8 and underwent clinical optimization of antihypertensive therapy. 9 Office BP was measured at least three times with the patients in a seated position, using a digital BP monitor (OMRON Healthcare Inc., Bannockburn, IL, USA). BP was considered the mean of the readings from the two different appointments.
After screening periods, patients were considered to have UCRH when BP was above goal despite the use of at least three drugs, with one ideally being a diuretic, or CRH when goal BP was achieved with use of four or more drugs. The hypertensive groups (UCRH and CRH) were matched for age, gender, body mass index, lipid profile and glucose metabolism. Non-pharmacological therapies were optimized including guidance on the control of dietary salt which was confirmed by the measurement of urinary sodium (o100 mEq per 24 h).
Laboratory assessment
Baseline blood samples for measurement of glycemia (mg dl À1 ), total cholesterol (mg dl À1 ), low-density lipoprotein cholesterol (mg dl À1 ), triglycerides (mg dl À1 ) and creatinine (mg dl À1 ) were collected at 0800 hours after overnight fasting, during which time individuals rested in the supine position for 8 h, followed by 1 h in an upright position in an air-conditioned room (22-24 1C) . Creatinine clearance (ml per min per 1.73 m 2 ), urinary Sodium (mEq l À1 ) and proteinuria (g per 24 h) were collected during 24 h.
24-h ABPM
The 24-h ABPM was carried out with an automatic oscillometric device (Spacelabs 90 207, Spacelabs Inc., Redmon, WA, USA). Patients were engaged in their normal daily activities and BP was measured automatically at 20-min intervals during an entire 24-h period. The following parameters were measured: average 24-h systolic, diastolic, mean and pulse pressures. A normal dipping pattern (dipper) was detected when the drop in the average systolic BP (SBP) during the night was 410% of the mean daytime SBP and an abnormal dipping pattern (non-dipper) was detected when the average reduction in nighttime SBP was o10% in respect to daytime values.
Endothelial function
Brachial artery dilatation was measured by ultrasound with a high resolution, linear vascular transducer (7-12 MHz, Toshiba Powervision 6000, Tokyo, Japan) coupled to computer-assisted analysis software and automated brachial analyzer software device (Brachial Analyzer, Medical Imaging Applications, Coralville, IA, USA).
Initially, the brachial artery responses to endothelial-dependent (flow-mediated dilation (FMD)) and independent (glyceryl-trinitrate mediated) stimuli were determined using a modification of the technique described by Celermajer et al. 10 and in accordance with current guidelines. 11 All studies were initiated at 00800 hours after overnight fasting, with the subjects in a supine position in a quiet, airconditioned room (22-24 1C) . Because of the ethical reasons, we decided not to discontinue treatment previous to FMD measurements, as this subset of patients usually present very elevated pressure levels. In brief, the subjects rested quietly for 15 min before the first scan and remained in the supine position throughout the study. The brachial artery was scanned longitudinally 5-10 cm above the elbow. When a satisfactory position had been found, a special probe holder was fixed around the arm to secure the ultrasound transducer in the same position through the measurements. 7 A polyurethane cuff (Hokanson Inc., Bellevue, WA, USA) placed above the transducer was inflated around the arm to a pressure of 250 mm Hg for 5 min and then rapidly deflated. The increased brachial artery diameter was recorded from 45 to 120 s after cuff deflation. Changes in the brachial artery diameter were expressed as a percent change relative to the vessel diameter immediately before cuff inflation. After allowing 10-15 min for brachial artery recovery, another baseline scan was taken. The response to glyceryl-trinitrate was used as a measure of endothelium-independent vasodilation. 12 After recording the second baseline scan, 0.4 mg of glyceryltrinitrate (Nitrostat, Parke-Davis, NJ, USA) was given sublingually and 4-5 min later the brachial artery was imaged. The response of the brachial artery diameter to nitroglycerin-mediated dilation (NTG) was expressed as a percentage change relative to the vessel diameter immediately before drug administration. 
Statistical analysis

Results
Clinical characteristics BP levels and the main clinical characteristics of the three study groups are shown in the Table 1 .
Anti-hypertensive drugs daily were similar in both subgroups (5.1±0.9 versus 3.8±0.7 in UCRH and CRH patients, respectively (P ¼ 0.06); Table 2 ). A multiple linear regression model including age, body mass index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol cholesterol, triglycerides, creatinine plasma levels, glomerular filtration rate and urinary sodium excretion did not show differences between UCRH and CRH. However, 72 and 58% patients in the UCRH and CRH groups, respectively, were classified as having metabolic syndrome.
Vascular function evaluation FMD testing indicated that the UCRH patients had greater impairment of endothelial function (5.9 ± 2.3%) compared with the CRH patients (7.1±5.1%; Po0.0001). In addition, FMD testing showed a significant difference between the two resistant hypertensive groups (UCRH and CRH) versus Nocturnal dipping and endothelial function in resistant hypertension T Quinaglia et al control subjects (12.2 ± 6.3%; Po0.0001 and P ¼ 0.0006, respectively; Figure 1) . The glyceryl-trinitrate responses in the UCRH and CRH groups were similar. In addition, a comparison with NT patients showed no significant differences for UCRH and CRH groups (P40.05 in both cases).
ABPM-nocturnal dipping
The nighttime drop in SBP and DBP were less pronounced in UCRH than in CRH patients (SBP, 1.9±1.6 versus 4.9±1.7%, respectively; DBP, 7.5 ± 1.8 versus 10.9 ± 1.8%, respectively Figure 2 ).
Quadratic linear regression showed an association (clusters) between blunted values of systolic dipping and impaired brachial artery flow-mediated dilatation in the NT, CRH and UCRH groups (Figure 3) . We found an association between decreased values of diastolic dipping and impaired brachial artery dilatations in the NT, CRH and UCRH groups (Figure 4) . Dipping status was not associated with the NTG-mediated vascular responses in the three groups.
Discussion
This study is novel in showing that RHTN is a heterogeneous group with two distinct subgroups. Patients with UCRH have a greater impairment of the endothelial function and lower nocturnal BP reductions than patients with CRH. These clinical and vascular differences between the two subgroups suggest important underlying differences in pathophysiology and differences in cardiovascular risk.
ABPM has been proven to provide more accurate prognostic information on cardiovascular outcomes than other readings of BP. [13] [14] Extensive studies have clearly demonstrated predictive information of cardiovascular outcomes in population-based surveys. [15] [16] [17] [18] [19] In addition to the mean 24-h BP, nocturnal BP has frequently been considered an important predictor of both target-organ damage and cardiovascular events. [18] [19] [20] A normal dipping pattern (dipper) is seen when the drop in the average SBP during the night is 410% of the mean daytime SBP. Individuals with a non-dipper pattern (reduction in nighttime SBP o10%) are at increased risk for cerebrovascular and cardiovascular complications Nocturnal dipping and endothelial function in resistant hypertension T Quinaglia et al when compared with individuals with a normal dipper profile. 16, [21] [22] [23] [24] [25] [26] Previous studies have shown that patients with UCRH and CRH both have blunted nocturnal drops in SBP and DBP. 3, 27 In these earlier publications, patients with RHTN have a high prevalence of nondipper pattern which contributes to an increased risk of cardiovascular events, 18 as well as a high prevalence of target organ damage at cardiac, macroand microvascular levels. 28 The results of this study show a cluster relation between impaired FMD and an abnormal dipper pattern of nocturnal SBP and DBP. Also, NTGinduced vascular responses were not associated with non-dipping of SBP and DBP in both UCRH and CRH patients. In fact, it is known that Figure 3 (a) Impairment of the brachial arterial flow-mediated dilatation is not related to decrease in systolic blood pressure dipping in normotensive healthy subjects. Inadequate flow-mediated dilatation occurs in 24% of patients with systolic non-dipper status. Tryceryltrinitrate-induced brachial artery dilatation is not related to decrease in systolic blood pressure dipping in normotensive healthy subjects. Inadequate GTN dilatation occurs in only 4% of patients with systolic non-dipper status. (b) Impairment of the brachial arterial flow-mediated dilatation is weakly related to decrease in systolic blood pressure dipping in controlled resistant hypertensive patients. Inadequate flow-mediated dilatation occurs in 48% of patients with systolic non-dipper status. Tryceryl-trinitrate-induced brachial artery dilatation is not related to decrease in systolic blood pressure dipping in controlled resistant hypertensive patients. Inadequate GTN dilatation occurs in only 43% of patients with systolic non-dipper status. (c) Impairment of the brachial arterial flow-mediated dilatation is largely related to decrease systolic in blood pressure dipping in uncontrolled resistant hypertensive patients. Inadequate flow-mediated dilatation occurs in 85% of patients with systolic non-dipper status. Tryceryl-trinitrate-induced brachial artery dilatation is not related to decrease in systolic blood pressure dipping in uncontrolled resistant hypertensive patients. Inadequate GTN dilatation occurs in only 27% of patients with systolic non-dipper status.
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T Quinaglia et al uncontrolled essential hypertensive patients show a markedly reduced response to endotheliumdependent vasodilatation compared with control subjects without significant differences in the response to NTG. 7 Probably, arterial smooth muscle cell was still not affected because of a relative short time of hypertension diagnosis. The phosphodiesterase-5/cyclic guanosine monophosphate pathway, which is activated by the NTG administered, apparently has an important role in maintaining balance of the vascular reactivity function, as there is limited endothelial nitric oxide (NO) bioactivity. However, despite been described in other studies, [29] [30] [31] the minimal or absent endothelium-independent vasodilation dysfunction in hypertensive patients is still unexplained. Figure 4 (a) Tryceryl-trinitrate-induced brachial artery dilatation is not related to decrease diastolic blood pressure dipping in normotensive healthy subjects. Inadequate GTN dilatation occurs in only 8 % of patients with diastolic non-dipper status. Impairment of the brachial arterial flow-mediated dilatation is not related to decrease in diastolic blood pressure dipping in normotensive healthy subjects. Inadequate flow-mediated dilatation occurs in 20% of patients with systolic non-dipper status. (b) Impairment of the brachial arterial flow-mediated dilatation is weakly related to decrease in diastolic blood pressure dipping in controlled resistant hypertensive patients. Inadequate flow-mediated dilatation occurs in 33% of patients with diastolic non-dipper status. Tryceryl-trinitrate-induced brachial artery dilatation is not related to decrease in diastolic blood pressure dipping in controlled resistant hypertensive patients. Inadequate GTN dilatation occurs in only 30% of patients with diastolic non-dipper status. (c) Impairment of the brachial arterial flowmediated dilatation is largely related to decrease in diastolic blood pressure dipping in uncontrolled resistant hypertensive patients. Inadequate flow-mediated dilatation occurs in 85% of patients with diastolic non-dipper status. Tryceryl-trinitrate-induced brachial artery dilatation is not related to decrease in diastolic blood pressure dipping in uncontrolled resistant hypertensive patients. Inadequate GTN dilatation occurs in only 29% of patients with diastolic non-dipper status.
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In addition, our results suggest that impaired NO bioavailability may be involved in both endothelial dysfunction and in the blunting of the BP nocturnal drop in UCRH patients. On the other hand, CRH patients showed varied associations between FMD, NTG-induced vascular responses, and SBP and DBP dipping. The current FMD results provide additional information on the data obtained from ABPM in view of the fact that FMD and SBP and DBP dipping are related to each other. The combination of these measurements will be of stronger clinical relevance, particularly in respect of uncontrolled resistant hypertensive patients with high cardiovascular risk.
In spite of using angiotensin-converting enzymes and/or angiotensin-receptor blockers, and calciumchannel blockers (for about 89% of the total RHTN individuals), which enhances basal NO release and thereby helps preserving endothelial function, 32 the FMD testing was impaired in both CRH and UCRH patients. In part, this could be explained by previous findings of our group that showed that combined therapy with an angiotensin-converting enzyme inhibitor þ angiotensin-receptor blocker can induce 'aldosterone escape' in hypertensive patients after 12 weeks of treatment. 33 In addition, evidence is emerging that mineralocorticoid receptor blockade is useful in treating hypertensive patients who have both metabolic syndrome and RHTN. 34 As few patients (6%) were taking aldosterone antagonists, it is tempting to speculate that this aldosterone escape contributed to endothelial dysfunction in both hypertensive groups. Recently, other investigators have demonstrated that the initial improvement in endothelial dysfunction caused by angiotensinconverting enzymes and angiotensin-receptor blockers in mild-to-moderate hypertension is not maintained after 1 year. 35 This finding has not been tested in resistant hypertensive patients.
A non-dipping BP can be found in subjects with obesity 36 and visceral obesity. 37 in addition, a higher occurrence of metabolic syndrome has been reported in non-dippers compared with dippers. 38 Accumulating evidence indicates that adipose tissue may produce aldosterone secretory factors that cause excessive adrenal aldosterone production. If true, a new paradigm is emerging that elevated levels of plasma aldosterone mediate several maladaptive changes that contribute to the pathogenesis of the metabolic syndrome and RHTN. 34 Moreover, it has been also demonstrated that elevated plasma aldosterone levels, which is far more common in resistant hypertensive patients (17-22%) than in the general hypertensive population, 1,39-42 directly contribute to the pathogenesis of insulin resistance and endothelial dysfunction. 34, 43 The associated cardiovascular and renal structural and functional abnormalities found in these patients may be a consequence of this endothelial dysfunction. 34, 44 In addition, metabolic syndrome itself is a condition in which circulating glucocorticoid concentrations are several orders of magnitude greater than normal range. Thus, by mineralocorticoid receptor activation, glucocorticoids promote inflammation, oxidative stress, fibrosis, insulin resistance and also endothelial dysfunction. [45] [46] [47] Moreover, because of insulin resistance, there is decreased insulin stimulation of endothelial NO synthase activation and increased NO destruction. 43 Our results clearly reveal a significant association between RHTN, non-dipping BP and endothelial dysfunction. In particular the UCRH group, besides having higher BP levels, tended to have higher body mass index, glycemia and lipids, and more pronounced impairment in BP dipping and endothelial function than the CRH patients. In our view, this finding reinforces the hypothesis that there is a link between the non-dipping BP pattern and endothelial dysfunction in RH.
It should be mentioned as limitations of this study that the NT group could not be matched by body mass index, glucose metabolism and lipid profile because this group was supposedly healthy, and also inadequacy of these parameters is highly prevalent in resistant hypertensive. We could not prevent ourselves either from including individuals with diabetes, which is known to affect endothelial function, because the sample size of subjects was small already.
We conclude that there is a cluster correlation between SBP dipping status and endothelial dysfunction in patients with RHTN, suggesting that vascular impairment likely contributes to the attenuated dipping BP pattern in this hypertensive group. Finally, our findings demonstrate important physiological differences between patients with controlled versus uncontrolled hypertension, suggestive of possible mechanistic differences related to their hypertension. We would anticipate that these differences reflect a worse cardiovascular prognosis in the UCRH group, but this needs testing with prospective assessments.
